Further to DrugAlert Volume 328, HPS Pharmacies wish to give notice that Pfizer Australia Pty Ltd are continuing to experience an interruption to the supply of Dantrium® vials as follows:
Dantrolene sodium 20mg
While wholesaler supplies of Dantrium® 20mg vials are exhausted, HPS Pharmacies can now source internationally registered Ryanodex® vials (dantrolene 250mg) due to an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989.
While the indication and route of administration are the same for each product, the process of reconstitution and final concentration differ significantly. Upon reconstitution, Ryanodex® 250mg vials yield a 50mg/ml suspension while Dantrium® 20mg vials produce a solution with a final concentration of ~0.33mg/ml.
Posters highlighting the differences between Ryanodex® and Dantrium® should be printed and displayed in areas where dantrolene vials are stored and administered. Prescribers should also familiarise themselves with the prescribing information.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Pfizer Australia on (02) 9850 3333.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.